BMS 777607

Drug Profile

BMS 777607

Alternative Names: ASLAN-002; BMS-777607; BMS-797669

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb
  • Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Cancer

Most Recent Events

  • 01 Dec 2016 Aslan Pharmaceuticals completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in Australia (NCT01721148)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 05 Dec 2012 Aslan Pharmaceuticals initiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in Australia (NCT01721148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top